In vivo studies of atherosclerosis in non-diabetic mouse models, including low-densitylipoprotein receptor or apolipoprotein E-deficient mice, demonstrated thatthiazolidindione PPARγ ligands reduced lesion formation [95–97] consistent with PPARγ-mediatedvascular protection in non-diabetic vascular disease. Here, PPARG is linked to atherosclerosis.